Next Article in Journal
Effect of Fe and Thermal Exposure on Mechanical Properties of Al-Si-Cu-Ni-Mg-Fe Alloy
Previous Article in Journal
Photoluminescence and Temperature Sensing Properties of Bi3+/Sm3+ Co-Doped La2MgSnO6 Phosphor for Optical Thermometer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Base-Controlled Regiospecific Mono-Benzylation/Allylation and Diallylation of 4-Aryl-5-indolyl-1,2,4-triazole-3-thione: Thio-Aza Allyl Rearrangement

1
Chemistry Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt
2
Department of Chemistry, University of Jyväskylä, P.O. Box 35, FI-40014 Jyväskylä, Finland
3
Chemistry Department, Faculty of Science, Alexandria University, P.O. Box 426, Alexandria 21321, Egypt
4
Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
5
Chemistry Department, Faculty of Science, Arish University, Al-Arish 45511, Egypt
*
Authors to whom correspondence should be addressed.
Crystals 2023, 13(7), 992; https://doi.org/10.3390/cryst13070992
Submission received: 24 May 2023 / Revised: 14 June 2023 / Accepted: 15 June 2023 / Published: 21 June 2023

Abstract

:
The regiospecific S-benzylation/allylation of two 4-aryl-5-indolyl-1,2,4-triazole-3-thione precursors was carried out using Et3N as a base. Allyl group migration from exocyclic sulfur to the triazole nitrogen (N3) was successfully achieved in a short time via thermal fusion without the need for any catalyst. The allylation of indole nitrogen, along with exocyclic sulfur or triazole nitrogen (N3), was carried out using K2CO3 as stronger base. S,N-Diallylated products were converted to N,N-diallylated analogues using a simple fusion approach. Structural analyses of the two newly synthesized hybrids 2b and 5b investigated via the X-ray diffraction of a single crystal combined with Hirshfeld calculations. The compound 5b was crystallized in a monoclinic crystal system and the P21/c space group, whereas in compound 2b, the crystal system comprises the less symmetric triclinic and P − 1 space group. The asymmetric unit contains one and two molecules of 5b and 2b, respectively, while the unit cell contains four molecules in both cases. Hirshfeld analysis was performed in both systems to analyze the non-covalent interactions that control molecular packing. For 5b, C…H, N…H, S…H, Cl…N and H…H interactions are the most significant. Their percentages are 23.7, 8.8, 4.5, 1.2 and 48.2, respectively. In the case of 2b, the Cl…C, S…N, C…H, H…H and N…H interactions have the upper hand in molecular packing. In one unit, the percentages of these contacts are 2.3, 0.9, 26.8, 38.7 and 9.3%, while in the other unit, the corresponding values are 4.4, 1.3, 22.1, 43.6 and 9.0%, respectively.

1. Introduction

Indole is a privileged structure and well known in the fields of chemistry and other disciplines due to its various applications in medicine, agrochemicals, and the industry [1]. In drug discovery, this indole motif has shown a high efficacy against [2] several types of cancers, including MCF-7 (breast cancer) [3], HepG-2 (human liver) and MOLT3 (T lymphoblast) cancer cells [4]; MES-SA/DX5 (human uterine sarcoma) and HCT15/CL02 (human colorectal) as multidrug resistant cancer cells [5]; and many other cancer type cell lines [6,7,8]. Enhanced biological activity has been reported in a combination of the indole scaffold and other pharmacophores, such as heterocycles [9,10] (e.g., thiazoles, triazoles, oxadiazole, etc.) or a functional group of sulphonamides [11,12]. The indole scaffold not only has a high efficacy against cancer but many other forms of biological activity, such as anti-microbial [13], anti-malarial [14], anti-HIV [15], anti-convulsant [16], anti-inflammatory [17], anti-vascular [18], anti-diabetes (as they are α-glucosidase inhibitor agents) [19], etc. [20,21,22,23,24].
The combination of the triazole motif with the indole scaffold has recently received great attention in drug discovery development due to the many important pharmacological applications of the triazole unit [25,26,27,28], as well as recently discovered compounds. Nowadays, drugs containing the triazole nucleus are available on the market, for example, Fluconazole, Maraviroc, and Letrozole and others. These triazoles work as corrosion inhibitors [29] and dentate ligands due to their coordination chemistry with fluorescent applications [30].
Many examples regarding the attachment of the indole ring to triazoles have been reported. This has been identified as an anti-cancer agent targeting pro-apoptotic Bcl-2-inhibitory [31] or EGFR and Akt inhibitors [22], as well as a PARP-1 active agent [24]. To synthesize a new material with divergent functionalities is an interesting challenge for many chemists.
Based on these findings and the continuation of our research program [32], we synthesized new S-alkylated products, as well as N-alkylated products derived from the combination of the indole scaffold and triazole core structure. The explored and assigned molecular structure is based on single-crystal X-ray diffraction analysis and Hirshfeld analysis study.
In this study, we successfully achieved regiospecific mono-allylation and regiospecific di-allylation. NMR and single-crystal X-ray diffraction analysis were efficiently used for structural analysis.

2. Materials and Methods

Melting points were determined using melting-point apparatus (SMP10) in open capillaries and remained uncorrected. Chemicals, reagents and solvents were purchased from Alfa Aesar and Sigma-Merck. The progress of reactions and purity of products were observed using thin-layer chromatography (TLC) on pre-coated plates with silica gel 60 F254 at a thickness of 0.25 mm (Merck). Nuclear magnetic resonance spectra (1H NMR and 13C NMR) were determined in CDCl3 and DMSO-d6 and recorded using Bruker AC 400 MHz spectrometers with TMS as an internal reference standard. δ (ppm) was used for chemical shift description and values of coupling constants were given in Hz. HREI mass spectra were recorded with a Finnigan MAT 95XP instrument. CHNS-microanalysis performed on a Flash EA-1112 instrument.

2.1. General Procedures

2.1.1. Method a: Synthesis of the S-Alkylated Products

The selected 4-aryl-triazole-thiones 1ab (1.0 mmol) and Et3N (1.1 mmol) in dry acetone (10 mL) was stirred for one hour, benzyl bromide or allyl bromide (1.1 mmol) was added portion-wise, and stirring was continued overnight. The solvent was removed under vacuum, water was added, and the formed precipitates were collected, dried and recrystallized from ethanol.
  • 3-(Benzylsulfanyl)-4-phenyl-5-(1H-indol-2-yl)-1,2,4-triazole (2a)
Yield: 70%, m.p. 248–249 °C. 1H NMR (400 MHz, DMSO-d6): δ 4.42 (s, 2H), 5.59 (d, 1H, J = 1.3 Hz,), 6.95 (t, 1H, J = 7.4 Hz), 7.15 (t, 1H, J = 7.6 Hz), 7.27–7.45 (m, 9H), 7.61–7.70 (m, 3H), 11.97 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 37.21, 101.89, 112.31, 120.20, 121.17, 123.60, 124.33, 127.65, 128.00, 128.39, 128.97, 129.45, 130.62, 131.10, 134.16, 137.00, 137.43, 149.67, 151.76; Elemental Analysis Calc. for [C23H18N4S]: C, 72.23; H, 4.74; N, 14.65; S, 8.38 found C, 72.35; H, 4.79; N, 14.53; S, 8.49.
  • 3-(Benzylsulfanyl)-4-(4-chlorophenyl)-5-(1H-indol-2-yl)-1,2,4-triazole (2b)
Yield: 65%, m.p. 242–243 °C. 1H NMR (400 MHz, DMSO-d6): δ 4.42 (s, 2H), 5.70 (s, 1H), 6.97 (t, 1H, J = 7.1 Hz), 7.16 (t, 1H, J = 7.2 Hz), 7.21–7.56 (m, 9H), 7.62–7.81 (m, 2H), 11.97 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 37.37, 101.04, 112.31, 120.24, 121.33, 123.68, 124.13, 127.67, 128.04, 128.99, 129.46, 130.38, 130.71, 133.04, 135.75, 137.01, 137.39, 149.59, 151.69; Elemental Analysis Calc. for [C23H17ClN4S]: C, 66.26; H, 4.11; Cl, 8.50; N, 13.44; S, 7.69 found C, 66.12; H, 4.28; Cl, 8.38; N, 13.48; S, 7.83.
  • 3-(All-1-ylsulfanyl)-4-phenyl-5-(1H-indol-2-yl)-1,2,4-triazole (3a)
Yield: 81%, m.p. 218–219 °C [Lit. [24], 214–216 °C]. 1H NMR (400 MHz, CDCl3): δ 3.96 (d, H, J = 6.8 Hz), 5.20 (d, 1H, Jcis = 9.9 Hz), 5.34 (d, 1H, Jtrans = 16.9 Hz), 5.78 (s, 1H), 5.95–6.05 (m, 1H), 7.06 (dd, 1H, J = 7.7, J = 8.0 Hz), 7.25 (dd, 1H, J = 7.7, J = 8.0 Hz), 7.36–7.96 (m, 7H,), 11.05 (br.s, 1H); 13C NMR (CDCl3, 100 MHz) δ 35.48, 102.74, 112.49, 119.12, 120.14, 120.99, 123.73, 127.78, 127.97, 130.29, 130.73, 132.61, 133.94, 136.93, 149.89, 152.34; HRMS (EI) calcd for C19H16N4S (M+): 332.1096. Found: 332.1090.
  • 3-(All-1-ylsulfanyl)-4-(4-chlorophenyl)-5-(1H-indol-2-yl)-1,2,4-triazole (3b)
Yield: 79%, m.p. 229–230 °C. 1H NMR (400 MHz, CDCl3): δ 3.95 (d, 2H, J = 7.0 Hz), 5.20 (d, 1H, Jcis = 10.0 Hz), 5.34 (d, 1H, Jtrans = 16.9 Hz), 5.82 (s, 1H), 5.93–6.03 (m, 1H), 7.08 (t, 1H, J = 7.4 Hz), 7.26 (t, 1H, J = 7.6 Hz), 7.38 (d, 2H, J = 8.5 Hz), 7.47 (d, 1H, J = 8.0 Hz), 7.64 (d, 3H, J = 8.5 Hz), 10.64 (br.s, 1H); 13C NMR (CDCl3, 100 MHz) δ 35.53, 102.65, 112.08, 119.24, 120.32, 121.10, 123.38, 123.94, 127.70, 129.25, 130.58, 132.28, 132.36, 136.64, 136.87, 149.58, 152.27; HRMS (EI) calcd for [C19H15N4SCl]: 366.0706. Found: 366.0730.

2.1.2. Method b: Fusion of the Allyl-sulfanyl Isomers (Syhthesis of the N-Allylated 4ab and N-,N-Diallylated Compounds 6ab)

Separately, the S-allylated compounds from 3ab (1.0 mmol) and S,N-diallylated compounds 5ab (1.0 mmol) were fused at temperatures just higher than the respective melting point for few minutes (about 5 min) until all S-allyl starting materials were converted to N-allyl analogues as monitored by TLC. The products were purified by recrystallization from EtOH.
  • 2-(All-1-yl)-4-phenyl-5-(1H-indol-2-yl)-3-thioxo-1,2,4-triazole (4a)
Yield: 76%, m.p. 165–166 °C. 1H NMR (400 MHz, CDCl3): δ 5.00 (d, 2H, J = 6.0 Hz), 5.42 (d, 1H, Jcis = 10.2 Hz), 5.47 (d, 1H, Jtrans = 17.2 Hz), 5.77 (s, 1H), 6.05–6.24 (m, 1H), 7.09 (t, 1H, J = 7.4 Hz), 7.27 (t, 1H, J = 7.4 Hz), 7.32–7.53 (m, 4H), 7.67–7.68 (m, 3H), 8.94 (br.s, 1H); 13C NMR (CDCl3, 100 MHz) δ 51.94, 105.26, 111.23, 119.76, 120.85, 121.73, 122.05, 124.93, 127.54, 128.61, 130.24, 130.70, 134.97, 136.24, 144.04, 168.65; HRMS (EI) calcd for [C19H16N4S]: 332.1096. Found: 332.1091.
  • 2-(All-1-yl)-4-(4-chlorophenyl)-5-(1H-indol-2-yl)-3-thioxo-1,2,4-triazole (4b)
Yield: 74%, m.p. 187–188 °C. 1H NMR (400 MHz, CDCl3): δ 4.97 (d, 2H, J = 6.0 Hz), 5.41 (dd, 1H, Jcis = 10.0, Jgem = 0.8 Hz), 5.44 (dd, 1H, Jtrans = 17.2, Jgem = 0.8 Hz), 5.87 (d, 1H, J = 1.2 Hz), 6.10–6.18 (m, 1H), 7.07 (dd, 1H, J = 8.0, J = 7.2 Hz), 7.25 (dd, 1H, J = 7.2, J = 8.0 Hz), 7.33–7.38 (m, 3H), 7.45 (d, 1H, J = 8.0 Hz), 7.59 (d, 2H, J = 8.4 Hz), 8.96 (br.s, 1H); 13C NMR (CDCl3, 100 MHz) δ 51.99, 105.26, 111.25, 119.90, 121.00, 121.82, 125.11, 127.50, 130.04, 130.56, 130.67, 133.38, 136.27, 136.79, 143.80, 168.66; HRMS (EI) calcd for [C19H15N4SCl]: 366.0706. Found: 366.0716.

2.1.3. Method c: Synthesis of S,N-Diallylated Compounds 5ab and N,N-Diallylated Compounds 6ab

Separately, (1.0 mmol) of the selected hit compounds 3-allylsulfanyl-4-aryl-triazole-thiones 3ab/2-(Allyl)-4-phenyl-5-indolyl-3-thioxo-1,2,4-triazoles 4ab and anhydrous K2CO3 (1.1 mmol) in dry acetone (10 mL) were stirred for one hour, allyl bromide (1.1 mmol) was added portion-wise and all mixtures were stirred overnight (reaction progress was monitored using TLC). Acetone was removed under vacuum, water was added, and the formed precipitates were collected, dried and recrystallized from ethanol.
  • 3-(All-1-ylsulfanyl)-5-((1-all-1-yl)-indol-2-yl)-4-phenyl-1,2,4-triazole (5a)
Yield: 51%, m.p. 116–117 °C [Lit. [24], 113–114 °C]. 1H NMR (400 MHz, CDCl3): δ 3.92 (d, 2H, J = 7.2 Hz), 4.84 (d, 1H, Jtrans = 17.2 Hz), 5.07 (d, 1H, Jcis = 10.4 Hz), 5.14 (d, 1H, Jcis = 10.0 Hz), 5.275–5.32 (m, 3H), 5.95–6.04 (m, 3H), 7.03 (dd, 1H, J = 8.0, J = 7.2 Hz), 7.19–7.24 (m, 3H), 7.33 (d, 1H, J = 8.4 Hz), 7.38 (d, 1H, J = 8.0 Hz), 7.47–7.52 (m, 3H); 13C NMR (CDCl3, 100 MHz) δ 35.22, 47.10, 105.51, 110.44, 116.12, 119.10, 120.24, 121.36, 123.47, 124.59, 126.95, 127.65, 130.00, 130.20, 132.58, 134.14, 137.73, 149.05, 152.30; HRMS (EI) calcd for [C22H20N4S]: 372.1409. Found: 372.1422.
  • 3-(All-1-ylsulfanyl)-5-((1-all-1-yl)-indol-2-yl)-4-(4-chlorophenyl)-1,2,4-triazole (5b)
Yield: 47%, m.p. 160–161 °C. 1H NMR (400 MHz, CDCl3): δ 3.92 (d, 2H, J = 7.2 Hz), 4.82 (d, 1H, Jtrans = 17.2, Jgem = 0.8 Hz), 5.06 (d, 1H, Jcis = 10.0, Jgem = 0.8 Hz), 5.15 (d, 1H, Jcis = 9.6 Hz), 5.28–5.33 (m, 3H), 5.95–6.04 (m, 3H), 7.06 (dd, 1H, J = 8.0, J = 7.2 Hz), 7.17 (d, 2H, J = 8.8 Hz), 7.23 (dd, 1H, J = 7.2, J 8.0 Hz), 7.34 (d, 1H, J = 8.0 Hz), 7.43 (d, 1H, J = 8.0 Hz), 7.47 (d, 2H, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 35.43, 47.04, 105.85, 110.46, 116.22, 119.22, 120.43, 121.45, 123.76, 124.01, 126.93, 128.95, 130.31, 132.31, 132.48, 134.06, 136.45, 137.89, 148.85, 152.25; HRMS (EI) calcd for C22H19N4SCl (M+): 406.1019. Found: 406.1022.
  • 2-(All-1-yl)-5-((1-all-1-yl)-indol-2-yl)-4-phenyl-3-thioxo-1,2,4-triazole (6a)
Yield: 73method b, 55method c%, m.p. 145–146 °C. 1H NMR (400 MHz, CDCl3): δ 4.89 (d, 1H, Jtrans = 17.2 Hz), 5.02 (d, 2H, J = 6.0 Hz), 5.08–5.12 (m, 3H), 5.36 (d, 1H, Jcis = 10.4, Jgem = 0.8 Hz), 5.42 (d, 1H, Jtrans = 17.2, Jgem = 0.8 Hz), 5.85–5.94 (m, 1H), 6.01 (s, 1H), 6.05–6.12 (m, 1H), 7.05 (dd, 1H, J = 8.0, J = 7.2 Hz), 7.23–7.32 (m, 4H), 7.40 (d, 1H, J = 0.8 Hz), 7.50–7.60 (m, 3H); 13C NMR (CDCl3, 100 MHz) δ 47.02, 51.92, 107.80, 110.34, 116.66, 119.74, 120.66, 121.78, 122.91, 124.29, 12670, 128.47, 129.85, 130.10, 130.80, 133.58, 135.28, 137.99, 143.63, 168.09; HRMS (EI) calcd for [C22H20N4S]: 372.1409. Found: 372.1390.
  • 2-(All-1-yl)-5-((1-all-1-yl)-indol-2-yl)-4-(4-chlorophenyl)-3-thioxo-1,2,4-triazole (6b)
Yield: 69method b, 51method c%, m.p. 174–175 °C. 1H NMR (400 MHz, CDCl3): δ 4.88 (d, 1H, Jtrans = 17.1 Hz), 5.00 (d, 2H, J 5.9 Hz), 5.09–5.14 (m, 3H), 5.42 (d, 1H, Jcis = 10.4 Hz), 5.46 (d, 1H, Jtrans = 17.2 Hz), 5.90–5.97 (m, 1H), 6.11–6.18 (m, 2H), 7.13 (t, 1H, J = 7.4 Hz), 7.29–7.51 (m, 7H); 13C NMR (CDCl3, 100 MHz) δ 46.95, 51.92, 107.80, 110.31, 116.69, 119.85, 120.76, 121.81, 122.55, 124.42, 126.61, 129.76, 130.11, 130.59, 133.47, 133.64, 136.10, 137.97, 143.36, 168.03; HRMS (EI) calcd for C22H19N4SCl (M+): 406.1019. Found: 406.1023.

2.2. Crystal Structure Determination

The technical method for determining crystal structures for compounds 5b and 2b is provided in supporting information [33,34,35,36], and crystal data are summarized in Table 1.

2.3. Hirshfeld Surface Analysis

Topology analyses were performed using Crystal Explorer 17.5 program [37].

3. Results and Discussion

The regiospecific S-benzylzation and S-allylation of 5-indolyl-4-phenyl-1,2,4-triazole-3-thione 1a and its 4-(4-chlorophenyl) analogue 1b were successfully performed via reaction with benzyl bromide and allyl bromide, respectively. This reaction was promoted by an Et3N base, which was used as a catalyst in an acetone medium (Scheme 1). 1H NMR and 13C NMR spectroscopy revealed the following characteristic signals that support structural assignments: benzylated products 2ab spectra contained methylene protons of the benzyl group (-CH2Ph) (almost at 4.42 ppm), and the respective methylene carbons were approximately at 37.30 ppm. The allylated compounds 3ab had allylic protons (attached to saturated sp3 carbon -S-CH2) as a doublet at 3.95 ppm, while the corresponding allylic carbon appeared to be near 35.50 ppm. In addition, the 1H NMR of 3ab displayed the cis protons of the vinylic methylene group at 5.20 ppm with a coupling constant value of 3J ≈ 10.0 Hz, whereas the trans proton was found at 5.34 ppm with 3J ≈ 16.9 Hz. The remaining vinylic CH proton was found as multiplet in the region at 5.95–6.05 ppm. The two triazole carbons in the four compounds 2ab, 3ab were detected near 149.00 and 152.00 ppm.
Moreover, a simple, efficient and catalyst-free thermal rearrangement of the allyl moiety from exocyclic sulfur to N(2) of the triazole ring was successfully carried out via the fusion of S-allylated compounds 3ab on a hotplate for a few minutes at temperatures just higher than their melting points to yield N-allylated compounds 4ab. The S-allylated triazoles 3ab were further allylated in the presence of the K2CO3 base, which catalyzed the allylation of indole nitrogen to afford the S,N-diallylated products 5ab. To obtain N,N-diallylated products 6ab, the allylation of indole nitrogen and triazole nitrogen was regiospecifically carried out either via the allylation of N-allylated precursors 4ab or via the thermal thio-aza allyl rearrangement of 5ab (Scheme 2). The allyl group migration from sulfur to nitrogen was supported by NMR spectra of 4a-b. The allylic methylene protons experienced a downfield chemical shift, appearing near 5.00 ppm where, the respective allylic methylene carbon shifted approximately to 51.90 ppm. In addition, one of the triazole carbon signals was shifted to 168.65 ppm, supporting C=S formation caused by allyl group migration.
Sulfur and indole nitrogen allylation in the compounds 5ab, was confirmed due to the disappearance of indole NH and the appearance of new allyl group signals. The S,N-diallylic methylene group protons signals were detected near 3.92 ppm (for SCH2) and 4.84 ppm (NCH2) and the respective carbons were detected at 35.22 ppm (for SCH2) and 47.10 ppm (for NCH2). The two triazole carbons were found near 149.00 and 152.00 ppm.
The allylation of indole nitrogen, along with triazole nitrogen 6ab, established based on NMR, which displayed the signals of the two allylic methylene groups near 4.89 ppm and 5.02 ppm and the respective allylic carbons found near 47.00 ppm and 52.00 ppm. Moreover, the appearance of a 13C NMR signal at 168.00 ppm strongly supports the thiocarbony group (C=S).

3.1. Crystal Structure Description

The structure of 5b is shown in Figure 1, which is found to have a good agreement with the proposed structure based on the spectral characterizations. Selected bond distances are shown in Table 2, while selected bond angles are depicted in Table S1 (Supplementary Data). The structure solution of compound 5b has unit cell parameters of a = 11.0242 (3) Å, b = 16.5074 (4) Å, c = 11.0507 (2), and β =97.688 (2)°. Hence, the crystal system is monoclinic, while the space group is P21/c. The asymmetric formula is one unit, while z = 4. The crystal density is 1.356 Mg/m3, and the unit cell volume is 1992.94 (8) Å3. There are a number of aromatic ring systems in which the three planar ring systems are not coplanar with one another. The mean plane of the triazole moiety, and the phenyl moiety has an angle of 77.36 (12)°. Additionally, the mean plane of the indole and triazole moieties is also twisted, and the twist angle in this case is less than 35.98 (11)°.
The molecular units of 5b are connected with each other via the N…H and S…H non-covalent contacts shown in Figure 2A. A list of the H-bond parameters is shown in Table 3. The donor–acceptor distances of these interactions are 3.456 (2) and 3.741 (6) Å for C14-H14…N4 and C22A-H22B…S1, respectively. The packing scheme for the molecular units along the ab plane is shown in Figure 2B.
The X-ray structure of 2b is shown in Figure 3. Crystal data and a list of the geometric parameters are depicted in Table 1 and Table 2, respectively. In this case, the crystal system is triclinic and the space group is P-1. The lattice parameters are a = 12.1537 (5) Å, b = 12.8679 (5) Å, c = 15.0994 (5) Å, α = 70.272 (3)°, β = 69.417 (3)°, and γ = 67.402 (4)°. The asymmetric unit is two molecules of 2b, while z = 4. The crystal density is 1.396 Mg/m3, and the unit cell volume is 1984.17 (15) Å3. In 2b, the twist angles between the triazole ring and the Cl-phenyl or indole rings are smaller than in 5b. For one molecule, the twist angles are 65.79 (10)° and 18.94 (12)°, respectively. The molecule with letter B in the atom numbering has twist angles of 75.34 (10)° and 21.40 (11)°, respectively.
The molecules of 2b are interconnected in the crystal via the N…H contacts, as depicted in Table 3 and Figure 4A. There are two types of non-covalent interactions: polar N-H…N and non-polar C-H…N. The polar hydrogen bonds, such as the N1-H1…N4B and N1B-H1B…N4 have donor–acceptor distances of 2.913 (2) and 2.920 (2) Å, respectively. On the other hand, the C-H…N interaction distances occurred at longer distances (3.025 (2)–3.440 (2) Å). The packing scheme for the molecular units of 2b is shown in Figure 4B.

3.2. Hirshfeld Surface Analysis

The analysis of intermolecular interactions in the crystal of 5b is presented in Figure 5. The most dominant contacts are the H…H (48.2%), C…H (23.7%), Cl…H (11.0%), N…H (8.8%) and S…H (4.5%). Other minor interactions such as Cl…N (1.2%) and C…N (1.1%) contacts were detected.
There are three important surfaces in the Hirshfeld analysis, which are shown in Figure 6. In the dnorm surface, the most important short contacts appeared as red spots. These red spots are related to C…H, N…H, S…H, Cl…N and H…H interactions. A list of the shortest intermolecular contacts detected in the crystal of 5b is shown in Table 4. The other two surfaces (shape index and curvedness maps) are important for inspecting the possibility of π–π stacking interactions. The absence of red and blue triangles in the shape index and flat areas of the curvedness map indicates the absence of π–π stacking interactions. In accordance with this observation, the %C…C and %C…N values are 0.7 and 1.1, respectively.
In Figure 7, the fingerprint plots of the C…H, N…H, S…H, Cl…N and H…H contacts are shown. The blue area in the fingerprint plot gave the percentage of each of these contacts, as shown in Figure 5. Additionally, the pattern of the fingerprint plot sheds light on the importance of intermolecular interactions. All contacts presented in Figure 7 appear as sharp spikes, indicating that these interactions have short interaction distances, mostly shorter than total vdWs radii of the interacting atoms.
In the case of the crystal structure of 2b, the results indicate the presence of two molecules as asymmetric formula. Hence, two surfaces for each molecule are presented in Figure 8. Analysis of the different intermolecular interactions in this crystal structure is presented in Table 5.
It is clear from Table 5 that there are some differences in the intermolecular interactions that occurred in units A and B. In both units, H…H, C…H, Cl…H and N…H are the most dominant interactions. Further inspection of the dnorm map indicated the importance of Cl…C, S…N, C…H, H…H and N…H interactions in the molecular packing of unit A, where all these interactions have the characteristics of short-distance interactions (Figure 9). The same is true for unit B, but Cl…C interactions are less important in this case, constituting a major difference between the two units. All short interactions and their distances are listed in Table 6.
Additionally, the presence of some C…C and C…N interactions of up to 4.2% and 1.7%, respectively, might indicate the presence of π–π stacking interactions. Actually, all C…C and C…N contacts have significantly longer interaction distances than the total vdWs radii of the interacting atoms. Additionally, the absence of π–π stacking interactions is evident from the curvedness and shape index maps.

4. Conclusions

The base used in the alkylation of 4-aryl-5-indolyl-1,2,4-triazole-3-thione precursors affects the structure of the final product. The regiospecific S-benzylation/ allylation occurred when Et3N used. Thio-aza allyl rearrangement was successfully achieved via thermal fusion of S-allylated scaffolds. The indole nitrogen was allylated along with exocyclic sulfur or triazole nitrogen (N3) using K2CO3. S,N-diallylated products were transformed into N,N-diallylated analogues via thermal fusion. The structure of the two compounds was confirmed via the X-ray diffraction of a single crystal. Their supramolecular structures were calculated based on Hirshfeld calculations. The molecular packing of 5b was found to be controlled by short C…H (23.7%), N…H (8.8%), S…H (4.5%), Cl…N (1.2%) and H…H (48.2%) contacts. On the other hand, the supramolecular structure of 2b depended on Cl…C, S…N, C…H, H…H and N…H interactions. Their percentages are calculated to be 2.3–4.4, 0.9–1.3, 26.8–22.1, 38.7–43.6, 9.3–9.0, respectively.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cryst13070992/s1, X-ray structure determinations; Table S1: Bond angles (°) for 2b and 5b.

Author Contributions

Conceptualization, E.E.S., A.T.A.B., A.A.M.S. and A.B.; methodology, E.E.S., A.A.M.S., A.T.A.B. and M.F.Y.; software, S.M.S. and M.H.; validation, E.E.S., A.T.A.B. and A.B.; formal analysis, M.F.Y., E.E.S. and A.T.A.B.; investigation, A.T.A.B.; resources, A.T.A.B. and A.B.; data curation, M.F.Y.; writing—original draft preparation, A.T.A.B.; writing—review and editing, E.E.S., A.T.A.B., A.B., S.M.S., M.F.Y., M.H. and A.A.M.S.; visualization, A.T.A.B. and A.B.; supervision, A.T.A.B.; project administration, A.B.; funding acquisition, A.B. All authors have read and agreed to the published version of the manuscript.

Funding

The paper was funded by Researchers Supporting Project (RSP2023R64), King Saud University, Riyadh, Saudi Arabia.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to extend their sincere appreciation to the Researchers Supporting Project (RSP2023R64), King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Elshaier, Y.A.; Nemr, M.T.; Al Refaey, M.; Fadaly, W.A.; Barakat, A. Chemistry of 2-vinylindoles: Synthesis and applications. New J. Chem. 2022, 46, 13383–13400. [Google Scholar] [CrossRef]
  2. Kochanowska-Karamyan, A.J.; Hamann, M.T. Marine indole alkaloids: Potential new drug leads for the control of depression and anxiety. Chem. Rev. 2010, 110, 4489–4497. [Google Scholar] [CrossRef] [Green Version]
  3. Hong, C.; Firestone, G.L.; Bjeldanes, L.F. Bcl-2 family-mediated apoptotic effects of 3, 3′-diindolylmethane (DIM) in human breast cancer cells. Biochem. Pharmacol. 2002, 63, 1085–1097. [Google Scholar] [CrossRef] [PubMed]
  4. Pingaew, R.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Synthesis and cytotoxicity of novel 2, 2′-bis-and 2, 2′, 2″-tris-indolylmethanes-based bengacarboline analogs. Arch. Pharm. Res. 2012, 35, 949–954. [Google Scholar] [CrossRef] [PubMed]
  5. Rahman, K.W.; Li, Y.; Wang, Z.; Sarkar, S.H.; Sarkar, F.H. Gene expression profiling revealed survivin as a target of 3, 3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res. 2006, 66, 4952–4960. [Google Scholar] [CrossRef] [Green Version]
  6. Yoo, M.; Choi, S.-U.; Choi, K.Y.; Yon, G.H.; Chae, J.-C.; Kim, D.; Zylstra, G.; Kim, E. Trisindoline synthesis and anticancer activity. Biochem. Biophys. Res. Commun. 2008, 376, 96–99. [Google Scholar] [CrossRef]
  7. Safe, S.; Papineni, S.; Chintharlapalli, S. Cancer chemotherapy with indole-3-carbinol, bis (3′-indolyl) methane and synthetic analogs. Cancer Lett. 2008, 269, 326–338. [Google Scholar] [CrossRef] [Green Version]
  8. Foderaro, T.A.; Barrows, L.R.; Lassota, P.; Ireland, C.M. Bengacarboline, a New β-Carboline from a Marine Ascidian Didemnum sp. J. Org. Chem. 1997, 62, 6064–6065. [Google Scholar] [CrossRef]
  9. Nagarsenkar, A.; Prajapti, S.K.; Guggilapu, S.D.; Birineni, S.; Kotapalli, S.S.; Ummanni, R.; Babu, B.N. Investigation of triazole-linked indole and oxindole glycoconjugates as potential anticancer agents: Novel Akt/PKB signaling pathway inhibitors. Med. Chem. Commun. 2016, 7, 646–653. [Google Scholar] [CrossRef]
  10. Kaminskyy, D.; Bednarczyk-Cwynar, B.; Vasylenko, O.; Kazakova, O.; Zimenkovsky, B.; Zaprutko, L.; Lesyk, R. Synthesis of new potential anticancer agents based on 4-thiazolidinone and oleanane scaffolds. Med. Chem. Res. 2012, 21, 3568–3580. [Google Scholar] [CrossRef]
  11. Pingaew, R.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Synthesis and structure–activity relationship of mono-indole-, bis-indole-, and tris-indole-based sulfonamides as potential anticancer agents. Mol. Divers. 2013, 17, 595–604. [Google Scholar] [CrossRef] [PubMed]
  12. Lai, C.J.; Bao, C.J.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D.G.; Yin, L.; Samson, M.; Forrester, J.; et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010, 70, 3647–3656. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Al-Quawasmeh, R.A.; Huesca, M.; Nedunuri, V.; Peralta, R.; Wright, J.; Lee, Y.; Young, A. Potent antimicrobial activity of 3-(4, 5-diaryl-1H-imidazol-2-yl)-1H-indole derivatives against methicillin-resistant Staphylococcus aureus. Bioorg. Med. Chem. Lett. 2010, 20, 3518–3520. [Google Scholar] [CrossRef]
  14. Mascal, M.; Modes, K.V.; Durmus, A. Concise photochemical synthesis of the antimalarial indole alkaloid decursivine. Angew. Chem. Int. Ed. Engl. 2011, 50, 4445–4446. [Google Scholar] [CrossRef] [PubMed]
  15. Sechi, M.; Derudas, M.; Dallocchio, R.; Dessi, A.; Bacchi, A.; Sannia, L.; Carta, F.; Palomba, M.; Ragab, O.; Chan, C.; et al. Design and synthesis of novel indole β-diketo acid derivatives as HIV-1 integrase inhibitors. J. Med. Chem. 2014, 47, 5298–5310. [Google Scholar] [CrossRef] [PubMed]
  16. Mandour, A.H.; El-Sawy, E.R.; Shaker, K.H.; Mustafa, M.A. Synthesis, anti-inflammatory, analgesic and anticonvulsant activities of 1, 8-dihydro-1-ary1-8-alkyl pyrazolo (3, 4-b) indoles. Acta Pharm. 2010, 60, 73–88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Narayana, B.; Ashalatha, B.V.; Vijayaraj, K.K.; Fernandes, J.; Sarojini, B.K. Synthesis of some new biologically active 1, 3, 4-oxadiazolyl nitroindoles and a modified Fischer indole synthesis of ethyl nitro indole-2-carboxylates. Bioorg. Med. Chem. 2005, 13, 4638–4644. [Google Scholar] [CrossRef]
  18. Ty, N.; Dupeyre, G.; Chabot, G.G.; Seguin, J.; Tillequin, F.; Scherman, D.; Michel, S.; Cachet, X. Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3′, 4′, 5′-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents. Bioorg. Med. Chem. 2008, 16, 7494–7503. [Google Scholar] [CrossRef]
  19. Islam, M.S.; Barakat, A.; Al-Majid, A.M.; Ali, M.; Yousuf, S.; Choudhary, M.I.; Khalil, R.; Ul-Haq, Z. Catalytic asymmetric synthesis of indole derivatives as novel α-glucosidase inhibitors in vitro. Bioorg. Chem. 2018, 79, 350–354. [Google Scholar] [CrossRef]
  20. Bi, W.; Bi, Y.; Xue, P.; Zhang, Y.; Gao, X.; Wang, Z.; Li, M.; Baudy-Floc’h, M.; Ngerebara, N.; Gibson, K.M.; et al. Synthesis and characterization of novel indole derivatives reveal improved therapeutic agents for treatment of ischemia/reperfusion (I/R) injury. J. Med. Chem. 2010, 53, 6763–6767. [Google Scholar] [CrossRef]
  21. Boraei, A.T.; Ghabbour, H.A.; Gomaa, M.S.; El Ashry, E.S.H.; Barakat, A. Synthesis and anti-proliferative assessment of triazolo-thiadiazepine and triazolo-thiadiazine scaffolds. Molecules 2019, 24, 4471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Boraei, A.T.A.; Gomaa, M.S.; El Sayed, E.S.H.; Duerkop, A. Design, selective alkylation and X-ray crystal structure determination of dihydro-indolyl-1,2,4-triazole-3-thione and its 3-benzylsulfanyl analogue as potent anticancer agents. Eur. J. Med. Chem. 2017, 125, 360–371. [Google Scholar] [CrossRef] [PubMed]
  23. Boraei, A.T.; Ashour, H.K.; El Sayed, H.; Abdelmoaty, N.; El-Falouji, A.I.; Gomaa, M.S. Design and synthesis of new phthalazine-based derivatives as potential EGFR inhibitors for the treatment of hepatocellular carcinoma. Bioorg. Chem. 2019, 85, 293–307. [Google Scholar] [CrossRef] [PubMed]
  24. Boraei, A.T.; Singh, P.K.; Sechi, M.; Satta, S. Discovery of novel functionalized 1, 2, 4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation. Eur. J. Med. Chem. 2019, 182, 111621. [Google Scholar] [CrossRef]
  25. Kaur, R.; Dwivedi, A.R.; Kumar, B.; Kumar, V. Recent developments on 1, 2, 4-triazole nucleus in anticancer compounds: A review. Anti-Cancer Agent. Med. Chem. 2016, 16, 465–489. [Google Scholar] [CrossRef]
  26. Ayati, A.; Emami, S.; Foroumadi, A. The importance of triazole scaffold in the development of anticonvulsant agents. Eur. J. Med. Chem. 2016, 109, 380–392. [Google Scholar] [CrossRef] [Green Version]
  27. Keri, R.S.; Patil, S.A.; Budagumpi, S.; Nagaraja, B.M. Triazole: A Promising Antitubercular Agent. Chem. Biol. Drug Des. 2015, 86, 410–423. [Google Scholar] [CrossRef]
  28. Kucukguzel, S.G.; Cikla-Suzgun, P. Recent advances bioactive 1, 2, 4-triazole-3-thiones. Eur. J. Med. Chem. 2015, 97, 830–870. [Google Scholar] [CrossRef]
  29. Guo, L.; Wu, M.; Leng, S.; Qiang, Y.; Zheng, X. Synergistic effect of purpald with tartaric acid on the corrosion inhibition of mild steel: From electrochemical to theoretical insights. Prot. Met. Phys. Chem. Surf. 2018, 54, 917–925. [Google Scholar] [CrossRef]
  30. Yan, D.; Xiang, Y.; Li, K.; Chen, Y.; Yang, Z.; Guo, D. Synthesis, characterization and properties of 1, 2, 4-triazolo [3–b][1,3,4] thiadiazole derivatives and their europium complexes. J. Mol. Struct. 2014, 1074, 487–495. [Google Scholar] [CrossRef]
  31. Hamdy, R.; Ziedan, N.; Ali, S.; El-Sadek, M.; Lashin, E.; Brancale, A.; Jones, A.T.; Westwell, A.D. Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents. Bioorg. Med. Chem. Lett. 2013, 23, 2391–2394. [Google Scholar] [CrossRef] [PubMed]
  32. Altowyan, M.S.; Haukka, M.; Soliman, S.M.; Barakat, A.; Boraei, A.T.A.; Aboelmagd, A. Stereoselective Synthesis of New 4-Aryl-5-indolyl-1,2,4-triazole S- and N-β-Galactosides: Characterizations, X-ray Crystal Structure and Hirshfeld Surface Analysis. Crystals 2023, 13, 797. [Google Scholar] [CrossRef]
  33. Rikagu Oxford Diffraction. CrysAlisPro; Rikagu Oxford Diffraction Inc.: Yarnton, UK, 2020. [Google Scholar]
  34. Sheldrick, G.M. Shelxt–integrated space-group and crystal-structure determination. Acta Cryst. 2015, A71, 3–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Cryst. 2015, C71, 3–8. [Google Scholar]
  36. Hübschle, C.B.; Sheldrick, G.M.; Dittrich, B. ShelXle: A Qt graphical user interface for SHELXL. J. Appl. Crystallogr. 2011, 44, 1281–1284. [Google Scholar] [CrossRef] [Green Version]
  37. Turner, M.J.; McKinnon, J.J.; Wolff, S.K.; Grimwood, D.J.; Spackman, P.R.; Jayatilaka, D.; Spackman, M.A. Crystal Explorer17. University of Western Australia. 2017. Available online: https://crystalexplorer.net/ (accessed on 30 July 2020).
Scheme 1. Synthesis of compounds 2ab and 3ab.
Scheme 1. Synthesis of compounds 2ab and 3ab.
Crystals 13 00992 sch001
Scheme 2. Synthesis of the target compounds 46.
Scheme 2. Synthesis of the target compounds 46.
Crystals 13 00992 sch002
Figure 1. X-Ray structure of 5b.
Figure 1. X-Ray structure of 5b.
Crystals 13 00992 g001
Figure 2. The N…H/S…H contacts (A) and packing view via N…H/S…H contacts (B) for 5b.
Figure 2. The N…H/S…H contacts (A) and packing view via N…H/S…H contacts (B) for 5b.
Crystals 13 00992 g002
Figure 3. Structure with atom numbering for 2b drawn using 30% probability level for thermal ellipsoids.
Figure 3. Structure with atom numbering for 2b drawn using 30% probability level for thermal ellipsoids.
Crystals 13 00992 g003
Figure 4. The N…H contacts (A) and molecular packing via N…H contacts (B) for 2b.
Figure 4. The N…H contacts (A) and molecular packing via N…H contacts (B) for 2b.
Crystals 13 00992 g004
Figure 5. Contact percentages in 5b.
Figure 5. Contact percentages in 5b.
Crystals 13 00992 g005
Figure 6. Hirshfeld surfaces of 5b: (A) C…H, (B) S…H, (C) Cl…N, (D) H…H.
Figure 6. Hirshfeld surfaces of 5b: (A) C…H, (B) S…H, (C) Cl…N, (D) H…H.
Crystals 13 00992 g006
Figure 7. Decomposed fingerprint plots for the short contacts in 5b.
Figure 7. Decomposed fingerprint plots for the short contacts in 5b.
Crystals 13 00992 g007
Figure 8. Hirshfeld surfaces of 2b.
Figure 8. Hirshfeld surfaces of 2b.
Crystals 13 00992 g008
Figure 9. Decomposed dnorm and fingerprint plots for the short contacts in unit A of 2b.
Figure 9. Decomposed dnorm and fingerprint plots for the short contacts in unit A of 2b.
Crystals 13 00992 g009
Table 1. Crystal data.
Table 1. Crystal data.
5b2b
CCDC no.2,264,1292,264,130
empirical formulaC22H19ClN4SC23H17ClN4S
fw406.92416.92
temp (K)120 (2) 120 (2)
λ (Å)0.71073 1.54184
cryst systMonoclinicTriclinic
space groupP21/c P 1 -
a (Å)11.0242 (3) 12.1537 (5)
b (Å)16.5074 (4) 12.8679 (5)
c (Å)11.0507 (2) 15.0994 (5)
α (deg)9070.272 (3)
β (deg)97.688 (2)69.417 (3)
γ (deg)9067.402 (4)
V3)1992.94(8)1984.17 (15)
Z44
ρcalc (mg/m3)1.3561.396
μ (Mo Kα) (mm−1)0.3122.818
No. reflns.23,30753,703
Completeness to theta = 25.242°100%
Completeness to theta = 67.684° 100%
Unique reflns.66198329
GOOF (F2)1.0371.034
Rint0.04750.0342
R1a (I ≥ 2σ)0.04610.0296
wR2b (I ≥ 2σ)0.11060.0747
a R1 = Σ||Fo| − |Fc||/Σ|Fo|. b wR2 = [Σ[w(Fo2Fc2)2]/Σ[w(Fo2)2]]1/2.
Table 2. Bond lengths (Å) for 5b and 2b. a.
Table 2. Bond lengths (Å) for 5b and 2b. a.
BondLength/ÅBondLength/Å
5b 2b
Cl(1)-C(16)1.7389 (13)Cl(1)-C(13)1.7325 (13)
S(1)-C(19)1.7418 (16)S(1)-C(16)1.7460 (14)
S(1)-C(20B)1.8204 (16)S(1)-C(17)1.8318 (14)
S(1)-C(20A)1.8204 (16)N(1)-C(1)1.3716 (18)
N(1)-C(7)1.386 (2)N(1)-C(8)1.3788 (17)
N(1)-C(11)1.3938 (19)N(2)-C(16)1.3740 (17)
N(1)-C(8)1.457 (2)N(2)-C(9)1.3755 (17)
N(2)-C(19)1.3732 (18)N(2)-C(10)1.4372 (16)
N(2)-C(12)1.3802 (18)N(3)-C(16)1.3096 (17)
N(2)-C(13)1.4364 (17)N(3)-N(4)1.3989 (16)
N(3)-C(19)1.3124 (18)N(4)-C(9)1.3131 (17)
N(3)-N(4)1.4027 (18)Cl(1B)-C(13B)1.7373 (13)
N(4)-C(12)1.3190 (17)
a List of bond angles are given in Table S1 (Supplementary Materials).
Table 3. Hydrogen bonds for 2b and 5b [Å and °].
Table 3. Hydrogen bonds for 2b and 5b [Å and °].
D-H…Ad(D-H)d(H…A)d(D…A)<(DHA)Symm. Code
5b
C14-H14…N40.952.583.456 (2)1541 − x, 1 − y, 1 − z
C22A-H22B…S10.952.873.741 (6) 1532 − x, 1 − y, 1 − z
2b
C17-H17B…N30.992.553.025 (2) 109
C19-H19…N30.952.63.388 (2)140
N1-H1…N4B0.86 (2) 2.08 (2)2.913 (2)164.1 (18)
N1B-H1B…N40.88 (2)0.88 (2)2.920 (2) 163.1 (18)
C11-H11…N30.952.593.440 (2)1491 − x, 1 − y, 1 − z
C15B--H15B…N1B 0.952.533.396 (2) 152−x, 2 − y, 1 − z
Table 4. Short contacts in 5b.
Table 4. Short contacts in 5b.
ContactDistanceContactDistance
H8B…H22D2.084H20A…C12.599
H22D…C82.696H17…C192.657
H22D…C102.607H21B…C52.747
H5…C172.762H14…N42.458
H20C…C22.580S1…H22B2.754
H20C…C12.531Cl1…N33.149
Table 5. The non-covalent interactions and their percentages in 2b.
Table 5. The non-covalent interactions and their percentages in 2b.
ContactAB
Cl…S0.00.3
Cl…N0.30.4
Cl…C4.42.3
Cl…H8.510.6
S…N1.30.9
S…C0.51.8
S…H5.83.2
N…N0.20.0
C…N1.71.5
N…H9.09.3
C…C2.74.2
C…H22.126.8
H…H43.638.7
Table 6. Short contacts in 2b.
Table 6. Short contacts in 2b.
ContactDistanceContactDistance
S1…N4B3.289H23…H17C2.121
N4B…H11.933H19…H2B2.075
N3…H112.479C14…H11B2.762
Cl1…C213.246C19…H12B2.756
H23…H17C2.121C19B…H52.776
H19…H2B2.075C11B…H152.567
H21…H5B2.122
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Salama, E.E.; Youssef, M.F.; Boraei, A.T.A.; Haukka, M.; Soliman, S.M.; Barakat, A.; Sarhan, A.A.M. Base-Controlled Regiospecific Mono-Benzylation/Allylation and Diallylation of 4-Aryl-5-indolyl-1,2,4-triazole-3-thione: Thio-Aza Allyl Rearrangement. Crystals 2023, 13, 992. https://doi.org/10.3390/cryst13070992

AMA Style

Salama EE, Youssef MF, Boraei ATA, Haukka M, Soliman SM, Barakat A, Sarhan AAM. Base-Controlled Regiospecific Mono-Benzylation/Allylation and Diallylation of 4-Aryl-5-indolyl-1,2,4-triazole-3-thione: Thio-Aza Allyl Rearrangement. Crystals. 2023; 13(7):992. https://doi.org/10.3390/cryst13070992

Chicago/Turabian Style

Salama, Eid E., Mohamed F. Youssef, Ahmed T. A. Boraei, Matti Haukka, Saied M. Soliman, Assem Barakat, and Ahmed A. M. Sarhan. 2023. "Base-Controlled Regiospecific Mono-Benzylation/Allylation and Diallylation of 4-Aryl-5-indolyl-1,2,4-triazole-3-thione: Thio-Aza Allyl Rearrangement" Crystals 13, no. 7: 992. https://doi.org/10.3390/cryst13070992

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop